356 related articles for article (PubMed ID: 11704839)
1. The differential sensitivity of Bc1-2-overexpressing human breast tumor cells to TRAIL or doxorubicin-induced apoptosis is dependent on Bc1-2 protein levels.
Ruiz de Almodóvar C; Ruiz-Ruiz C; Muñoz-Pinedo C; Robledo G; López-Rivas A
Oncogene; 2001 Oct; 20(48):7128-33. PubMed ID: 11704839
[TBL] [Abstract][Full Text] [Related]
2. Stimulation of the mitogen-activated protein kinase pathway antagonizes TRAIL-induced apoptosis downstream of BID cleavage in human breast cancer MCF-7 cells.
Sarker M; Ruiz-Ruiz C; Robledo G; López-Rivas A
Oncogene; 2002 Jun; 21(27):4323-7. PubMed ID: 12082620
[TBL] [Abstract][Full Text] [Related]
3. Tumor necrosis factor-related apoptosis-inducing ligand retains its apoptosis-inducing capacity on Bcl-2- or Bcl-xL-overexpressing chemotherapy-resistant tumor cells.
Walczak H; Bouchon A; Stahl H; Krammer PH
Cancer Res; 2000 Jun; 60(11):3051-7. PubMed ID: 10850456
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapeutic agents sensitize sarcoma cell lines to tumor necrosis factor-related apoptosis-inducing ligand-induced caspase-8 activation, apoptosis and loss of mitochondrial membrane potential.
Hotta T; Suzuki H; Nagai S; Yamamoto K; Imakiire A; Takada E; Itoh M; Mizuguchi J
J Orthop Res; 2003 Sep; 21(5):949-57. PubMed ID: 12919886
[TBL] [Abstract][Full Text] [Related]
5. Resistance of mitochondrial DNA-deficient cells to TRAIL: role of Bax in TRAIL-induced apoptosis.
Kim JY; Kim YH; Chang I; Kim S; Pak YK; Oh BH; Yagita H; Jung YK; Oh YJ; Lee MS
Oncogene; 2002 May; 21(20):3139-48. PubMed ID: 12082629
[TBL] [Abstract][Full Text] [Related]
6. Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II.
Ravi R; Bedi A
Cancer Res; 2002 Aug; 62(15):4180-5. PubMed ID: 12154014
[TBL] [Abstract][Full Text] [Related]
7. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo.
Singh TR; Shankar S; Chen X; Asim M; Srivastava RK
Cancer Res; 2003 Sep; 63(17):5390-400. PubMed ID: 14500373
[TBL] [Abstract][Full Text] [Related]
8. Involvement of proapoptotic molecules Bax and Bak in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced mitochondrial disruption and apoptosis: differential regulation of cytochrome c and Smac/DIABLO release.
Kandasamy K; Srinivasula SM; Alnemri ES; Thompson CB; Korsmeyer SJ; Bryant JL; Srivastava RK
Cancer Res; 2003 Apr; 63(7):1712-21. PubMed ID: 12670926
[TBL] [Abstract][Full Text] [Related]
9. Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis.
Lacour S; Hammann A; Wotawa A; Corcos L; Solary E; Dimanche-Boitrel MT
Cancer Res; 2001 Feb; 61(4):1645-51. PubMed ID: 11245478
[TBL] [Abstract][Full Text] [Related]
10. Mitochondria-dependent and -independent mechanisms in tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis are both regulated by interferon-gamma in human breast tumour cells.
Ruiz-Ruiz C; López-Rivas A
Biochem J; 2002 Aug; 365(Pt 3):825-32. PubMed ID: 11936954
[TBL] [Abstract][Full Text] [Related]
11. Reactive oxygen species regulate caspase activation in tumor necrosis factor-related apoptosis-inducing ligand-resistant human colon carcinoma cell lines.
Izeradjene K; Douglas L; Tillman DM; Delaney AB; Houghton JA
Cancer Res; 2005 Aug; 65(16):7436-45. PubMed ID: 16103097
[TBL] [Abstract][Full Text] [Related]
12. Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells.
Izeradjene K; Douglas L; Delaney A; Houghton JA
Clin Cancer Res; 2004 Oct; 10(19):6650-60. PubMed ID: 15475455
[TBL] [Abstract][Full Text] [Related]
13. Bcl-2 inhibitors sensitize tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by uncoupling of mitochondrial respiration in human leukemic CEM cells.
Hao JH; Yu M; Liu FT; Newland AC; Jia L
Cancer Res; 2004 May; 64(10):3607-16. PubMed ID: 15150119
[TBL] [Abstract][Full Text] [Related]
14. Failure of Bcl-2 to block mitochondrial dysfunction during TRAIL-induced apoptosis. Tumor necrosis-related apoptosis-inducing ligand.
Kim EJ; Suliman A; Lam A; Srivastava RK
Int J Oncol; 2001 Jan; 18(1):187-94. PubMed ID: 11115558
[TBL] [Abstract][Full Text] [Related]
15. Death receptor 4 (DR4) efficiently kills breast cancer cells irrespective of their sensitivity to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
Kazhdan I; Marciniak RA
Cancer Gene Ther; 2004 Oct; 11(10):691-8. PubMed ID: 15354201
[TBL] [Abstract][Full Text] [Related]
16. Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance.
Ng CP; Zisman A; Bonavida B
Prostate; 2002 Dec; 53(4):286-99. PubMed ID: 12430140
[TBL] [Abstract][Full Text] [Related]
17. Defining characteristics of Types I and II apoptotic cells in response to TRAIL.
Ozören N; El-Deiry WS
Neoplasia; 2002; 4(6):551-7. PubMed ID: 12407450
[TBL] [Abstract][Full Text] [Related]
18. Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin.
Zhang XD; Wu JJ; Gillespie S; Borrow J; Hersey P
Clin Cancer Res; 2006 Feb; 12(4):1355-64. PubMed ID: 16489094
[TBL] [Abstract][Full Text] [Related]
19. Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL.
Voelkel-Johnson C; King DL; Norris JS
Cancer Gene Ther; 2002 Feb; 9(2):164-72. PubMed ID: 11857034
[TBL] [Abstract][Full Text] [Related]
20. Adriamycin sensitizes the adriamycin-resistant 8226/Dox40 human multiple myeloma cells to Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-mediated (TRAIL) apoptosis.
Jazirehi AR; Ng CP; Gan XH; Schiller G; Bonavida B
Clin Cancer Res; 2001 Dec; 7(12):3874-83. PubMed ID: 11751478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
